EZH2 and cancer: These observations suggest that while inhibition of EZH2 in cancer cells can promote anti-tumor immunity by enhancing recruitment of T effector cells in the tumor microenvironment [91, 92], inhibition of EZH2 on T cells may suppress survival, expansion and efficacy of such tumor-specific effectors thereby inducing the opposite effect.